Immunic (NASDAQ:IMUX) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Immunic (NASDAQ:IMUX) received a "sell (D-)" rating from Weiss Ratings, while multiple other analysts have issued "buy" ratings with varying price targets.
• As of the latest report, the stock has a consensus rating of "Moderate Buy" with an average target price of $9.50.
• Immunic's recent financial results showed a loss of ($0.20) earnings per share, missing expectations, and institutional investors collectively hold over 51% of the company's shares.

Immunic (NASDAQ:IMUX - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

A number of other brokerages have also commented on IMUX. Chardan Capital assumed coverage on shares of Immunic in a report on Monday, September 29th. They set a "buy" rating and a $13.00 price target on the stock. D. Boral Capital reiterated a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Thursday, September 25th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Immunic in a report on Friday, September 26th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $9.50.

Immunic Stock Performance

NASDAQ IMUX opened at $0.90 on Wednesday. The firm's fifty day moving average price is $0.88 and its two-hundred day moving average price is $0.91. The stock has a market cap of $88.54 million, a PE ratio of -0.95 and a beta of 1.56. Immunic has a fifty-two week low of $0.56 and a fifty-two week high of $1.73.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). As a group, sell-side analysts predict that Immunic will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

Several hedge funds and other institutional investors have recently bought and sold shares of IMUX. Aberdeen Group plc acquired a new position in Immunic in the first quarter valued at $1,155,000. 683 Capital Management LLC lifted its holdings in Immunic by 28.6% in the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock valued at $981,000 after buying an additional 200,000 shares during the period. Jane Street Group LLC lifted its holdings in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after buying an additional 152,726 shares during the period. Finally, Focus Partners Wealth lifted its holdings in Immunic by 19.1% in the first quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after buying an additional 415,104 shares during the period. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.